NY-LEMONADE
11.6.2019 14:35:10 CEST | Business Wire | Press release
Lemonade launched its first European country today. Consumers in Germany can now get contents and liability insurance instantly, anytime, and from any device - and they can file claims and get paid in seconds.
Founded by tech veterans Daniel Schreiber and Shai Wininger, Lemonade is powered by artificial intelligence and driven by social good. Unlike the traditional insurance model, Lemonade takes a flat fee for its operations, and gives remaining underwriting profit to nonprofits, as part of its annual Giveback. The company launched its homeowners and renters insurance in New York in late 2016, and has been one of the fastest growing insurance companies ever since.
Today’s launch in Germany marks a first for the insurance industry: Policy 2.0 , a new insurance policy designed for the 21st century. Policy 2.0 is a short, easy to understand, and transparent document that was designed for ordinary people and not for lawyers. Germany is the first country to offer Lemonade’s Policy 2.0, a consumer-friendly departure from the dense and dated policies available.
“We chose Germany for our first international launch because it combines a very traditional insurance industry, with a very forward thinking, digital-first consumer,” said Shai Wininger, Chief Lemonade Maker and cofounder of Lemonade. “Insurance that is instant, transparent, affordable, and mission-driven has universal appeal, which is why we look forward to launching in many more countries in the months and years to come.”
Lemonade enters the German market in partnership with AXA Germany, having entered into a multi-year reinsurance agreement to share insurance-related risk. The partnership connects the market expertise and broad networks of a global leader with Lemonade’s refreshing business model and instant everything technology.
“Rethinking insurance from a customer’s perspective is key to our mission. Therefore, AXA fosters self-driven innovation and partnerships more than ever. Our cooperation with Lemonade is strategically oriented, with reinsurance representing a first step in this direction,” said Alexander Vollert, CEO AXA Germany.
Lemonade is licensed and supervised by the Dutch Central Bank (DNB), and has established its European headquarters in Amsterdam. The company chose to set up operations in the Netherlands and found a collaborative and seasoned regulatory environment, coupled with a centralized hub of talent from around the world.
Residents of Germany can now buy a new policy or switch from an existing insurer through the Lemonade App or on www.lemonade.com/de . Stay updated on where Lemonade is launching next here .
About Lemonade
Lemonade is a licensed insurance carrier, offering homeowners and renters insurance in the US and contents and liability insurance in Germany. Powered by artificial intelligence and behavioral economics, Lemonade replaces brokers and bureaucracy with bots and machine learning, aiming for zero paperwork and instant everything. As a Certified B-Corp, where underwriting profits go to nonprofits, Lemonade is remaking insurance as a social good, rather than a necessary evil. Lemonade is currently available for most of the United States and Germany, and continues to expand globally.
Stay in touch at @lemonade_inc or www.facebook.com/lemonade
About AXA Germany
With written premiums of EUR 10.7 billion (2018) and 9,038 employees, AXA Konzern is one of the leading insurance companies and financial services providers in Germany. The company provides comprehensive solutions in the fields of private and company financial protection, health insurance, Property and Casualty insurance and asset management. The mindset and actions of the company are based on the customer and his needs. AXA Germany is part of the AXA Group, one of the worldwide leading insurance and asset management companies with 171,000 employees serving 105 million clients in 61 countries. In 2018, AXA Group IFRS revenues amounted to Euro 102.9 billion and IFRS underlying earnings to Euro 6.2 billion. AXA Group had Euro 1,424 billion in assets under management as of December 31, 2018.
Stay in touch at www.axa.de/medien , @AXADeutschland
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005538/en/
Contact:
LEMONADE Alexandra Ezra press@lemonade.com AXA Anja Knoll Anja.Kroll@axa.de
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom